A recent study weighed the benefits of yearly prostate cancer screening, finding that the potential disadvantages decrease the potential advantages by 23%. Harmful results of yearly prostate screening include negative prostate biopsies, radical prostatectomy, and radiation therapy.
A recent study found a relationship between the SPARCL1 gene and prostate cancer recurrence. Individuals who had lower activity of the gene had a higher risk of prostate cancer recurrence over 10 years. A test to detect SPARCL1 is being designed.
The New England Journal of Medicine | Oct 25, 2012
The utility of (prostate-specific antigen) PSA screening to inform prostate cancer diagnosis and treatment has been a topic of heated debate. The New England Journal of Medicine (NEJM) conducted a poll that indicates a lack of consensus among clinicians regarding best prostate cancer screening practices. Many clinicians feel patients should make informed decisions regarding testing preferences.
The FDA has approved enzalutamide (sold as Xtandi) 3 months ahead of deadline. The drug improved survival by nearly 5 months in men with advanced prostate cancer. It is approved for individuals who have not responded to chemotherapy. However, manufacturers hope to expand approval to include patients not previously treated with chemotherapy.
A recent study evaluated androgen deprivation therapy with and without radiation therapy in individuals with locally advanced prostate cancer. Individuals who received combination treatment had a better overall survival rate. Bowel-related side effects were similar for both groups 24 months after treatment.
A recent study evaluated the effects of beta-carotene antioxidant supplements in patients undergoing radiation therapy for advanced prostate cancer. Researchers were concerned that the supplements could reduce the benefits of radiation. The study followed participants for 10 years and did not find a difference in progression to lethal prostate cancer in individuals who took beta-carotene and those who did not.
A recent study evaluated the use of sildenafil (Viagra) for preventing sexual side effects when taken after radiation therapy for prostate cancer. Participants were treated with sildenafil for 6 months and evaluated for 2 years. Erectile function questionnaire scores were significantly higher in the group who received sildenafil, suggesting an overall improvement in sexual satisfaction in these individuals.
Accuray Incorporated announced positive data for CyberKnife stereotactic body radiation therapy (SBRT) for the treatment of cancer confined to the prostate. Several studies indicate that SBRT is as effective and possibly less toxic than traditional radiotherapy. Treatment with SBRT was effective with far fewer treatment sessions than are often required with traditional radiotherapy.
Annals of Cancer Research and Therapy | Sep 28, 2012
Bevacizumab (Avastin), which is approved for treatment of a number of advanced-stage cancer types, is commonly avoided in patients with brain metastases (cancer that has spread to the brain) because of fear of brain hemorrhages (bleeding in the brain). A retrospective study of 52 patients with advanced non-small cell lung cancer (NSCLC) who had received chemotherapy containing Avastin found no cases of serious bleeding events and no significant differences in survival or treatment side effects between patients with or without brain metastases. Avastin may therefore be a safe treatment option in NSCLC with brain metastases.
Research paper: https://www.jstage.jst.go.jp/article/acrt/20/2/20_47/_pdf